Clinical Trial Update: A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating whether combination therapy with Fianlimab and Cemiplimab is safer and more effective than anti-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cemiplimab (cemiplimab)
• Fianlimab (fianlimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING